Dr. Venugopal Arroju
Clinical Director & HOD Medical Oncology Senior Consultant Medical Oncologist & Hemato-Oncologist
Qualifications
MD (General Medicine), DM (Medical Oncology),
MRCP – SCE Medical Oncology (UK), ECMO (Switzerland).
Experience
15+ years
Book Appointment
Dr. Venugopal Arroju, the Clinical Director and Head of Department at Pi Health Cancer Hospital, brings extensive expertise and dedication to the team. He holds an MD in General Medicine, a DM in Medical Oncology, and MRCP credentials from the UK.
With over 15 years of experience, including roles at Apollo Hospitals and Yashoda Hospital, Dr. Venugopal has made significant contributions to cancer treatment and research. Known for his compassionate, patient-focused approach, he specializes in immunotherapy, targeted therapy, and precision oncology, particularly for lung, breast, gynecological, and colorectal cancers.
His research is widely recognized, with numerous publications and active participation in international conferences. As a leader, he ensures that Pi Health Cancer Hospital provides innovative, world-class cancer care.
- 2013–2016: DM (Medical Oncology) – Kidwai Memorial Institute of Oncology, RGUHS, Bangalore
- 2010–2013: MD (General Medicine) – M.S. Ramaiah Medical College, RGUHS, Bangalore
- Trained in Good Clinical Practices (GCP)
- Conducted Phase III Clinical Trials (TNBC and Her2+ Breast Cancer)
- Expert in Solid Tumors, Hematological Malignancies, Chemotherapy, Bone Marrow Transplantation
- Immunotherapy
- Targeted Therapy
- Precision Oncology
- Molecular Oncology
- Lung Cancer
- Breast Cancer
- Gynecological Cancers
- Colorectal Cancer
- American Society of Clinical Oncology (ASCO)
- European Society of Clinical Oncology (ESMO)
- Indian Society of Medical and Pediatric Oncology (ISMPO)
- Indian Cooperative Oncology Network (ICON)
- Adrenal Cortical Cancer from a Regional Cancer Center in South India
- Primary Parotid Lymphoma from a Regional Cancer Center in South India
- Ovarian Non-Hodgkin’s Lymphoma from a Regional Cancer Center in South India
- A randomized prospective study comparing the efficacy and safety of olanzapine vs aprepitant in highly emetogenic chemotherapy
- ESMO – Paris
- ASKO 2023 – Chicago
- ASH 2018 – San Diego
- SPEAK 2014 – Mumbai
- VICON 2014 – Vydehi Institute, Bangalore
- Pediatric Oncology CME – Shankara Cancer Hospital, Bangalore
- COPE Meeting 2015 – Chennai
- SPEAK 2015 – Mumbai
- COPE Meeting 2016 – Chennai
- Young Medical Oncologists Meet – Hyderabad
- Advances in Radiation Treatment – IMRT and Beyond
- CME on Gastric and OG Junction Cancers – Update
FAQS
1. Why do patients frequently visit Dr. A. Venugopal?
Patients frequently visit Dr. A. Venugopal for expert guidance and personalized care in medical oncology, including the management of solid tumors, hematological malignancies, and chemotherapy administration.
2. What are Dr. A. Venugopal's educational qualifications?
Dr. A. Venugopal holds an MD in General Medicine, a DM in Medical Oncology, and MRCP credentials in Medical Oncology. His extensive training and academic background make him a highly sought-after specialist in the field.
3. What does Dr. A. Venugopal specialize in?
Dr. A. Venugopal specializes in medical oncology, with a focus on the diagnosis, treatment, and management of various cancers, including solid tumors and hematological malignancies.
4. Where does Dr. A. Venugopal practice?
Dr. A. Venugopal practices at Pi Health Cancer Hospital in Hyderabad, India, where he serves as the Head of the Department and Senior Consultant in Medical Oncology.
5. How can I book an appointment with Dr. A. Venugopal - Best Medical Onclogost and Hemato-Oncologist?
You can book an appointment with Dr. A. Venugopal by contacting Pi Health Cancer Hospital directly or through our website, pihealthcancerhospital.com.
6. How many years of experience does Dr. A. Venugopal have?
Dr. A. Venugopal has over 15 years of experience in the field of medical oncology, during which he has provided compassionate care and innovative treatment solutions to patients battling cancer.